Stock market analyst Hitendra Vasudeo of stockmechanics.com maintained ‘Buy’ rating on GlaxoSmithkline Consumer Healthcare Ltd to achieve a short term target between Rs 1009 – Rs 1054.

According to Mr. Vasudeo, interested investors can buy the stock around Rs 982.70-Rs 965.30 with a strict stop loss of Rs 940.

Today (July 13), the shares of the company opened at Rs 990 as against it last closure of Rs 992.05 on the Bombay Stock Exchange (BSE). Current EPS & P/E ratio stood at 51.28 & 18.92 respectively. The share price has seen a 52-week high of Rs 1009.60 and a low of Rs 480 on BSE.

GlaxoSmithKline Consumer Healthcare, on July 06, has rolled out a national TV campaign for its Panadol Advance Tablets.

The advertisings, which break on 13 July and run through August, are part of a £3.7 million spend on the brand during the existing year.

For the three month period ended March 2009, GlaxoSmithkline Consumer Healthcare (GSK Consumer Healthcare) recorded a substantial growth in its standalone net profit.

During the period, the company’s profit surged 48.22% to Rs 838.90 million as against Rs 566.00 million during the corresponding period of the last year.

Net sales during the period increased 31.36% to Rs 5,393.70 million, whereas total income for the period surged 31.64% to Rs 5,650.10 million.

It posted EPS of Rs 19.95 during the period under review, posting 48.33% growth over previous year period.

During the first quarter, the company’s operating margin zoomed up by 517.07 basis points to 22.00% as against the last previous year period.

Interest cost climbed up by 1.54% to Rs 13.20 million, whereas depreciation cost increased marginally 0.09% to Rs 106.10 million over previous year period.